Yacht announced the completion of A round of financing of more than 100 million yuan. After the completion of this round of financing, Yacht will continue to strengthen the construction of independent R&D capacity, accelerate the industrialization of clinically urgently needed varieties, enhance the critical development and international sales capacity of characteristic APIs, quickly promote the R&D of innovative drug varieties, improve the construction of industrialization base, improve the production capacity of approved varieties, and quickly grow into an important player in the field of high-end microbial drugs.

Founded in 2004, Yacht is a developer of biomedicine and biochemical technology. The company is based on new drug development and research, process improvement and drug structure analysis of major drug products, drug quality research, and formulation of quality standards, involving anti-tumor drugs, anti-infective drugs, cardiovascular drugs, immune system drugs, and other fields.

The company has established a national microbial drug engineering research center and a provincial international science and technology cooperation base and has a rich microbial strain library, metabolite sample library, physiologically active substance screening platform, and structural modification platform. Through unique microbial source enzyme catalysis technology, genetic breeding technology, and synthetic biology means, the company continues to optimize the process and develop innovative drugs, At present, it has completed the whole industrial chain coverage from high-end microbial API to market sales.